1h Free Analyst Time
The plasma protease C1 inhibitor market is forecasted to grow by USD 2.00 bn during 2023-2028, accelerating at a CAGR of 7.55% during the forecast period. The report on the plasma protease C1 inhibitor market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing research and development in plasma protease C1 inhibitor, increasing product approvals/launches of plasma protease C1inhibitor, and technological advancements in plasma protease C1 inhibitor.
The plasma protease C1 inhibitor market is segmented as below:
By End-user
- Hospital pharmacy
- Retail pharmacy
- Online pharmacy
By Product
- Lyophilized
- Injectable
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the plasma protease C1 inhibitor market covers the following areas:
- Plasma protease C1 inhibitor market sizing
- Plasma protease C1inhibitor market forecast
- Plasma protease C1 inhibitor market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by End-user
7 Market Segmentation by Product
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global plasma protease C1 inhibitor market: AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bio Techne Corp., BioCryst Pharmaceuticals Inc., Biosynth Ltd., Bristol Myers Squibb Co., Cayman Chemical, CSL Ltd., FibroGen Inc., Fresenius SE and Co. KGaA, Gilead Sciences Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Merck KGaA, Novartis AG, Pharming Group NV, Sino Biological Inc., Takeda Pharmaceutical Co. Ltd., Thermo Fisher Scientific Inc., and Vertex Pharmaceuticals Inc..Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is growing adoption of bradykinin B2 receptor antagonist.'
According to the report, one of the major drivers for this market is the increasing research and development in plasma protease C1 inhibitor.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bio Techne Corp.
- BioCryst Pharmaceuticals Inc.
- Biosynth Ltd.
- Bristol Myers Squibb Co.
- Cayman Chemical
- CSL Ltd.
- FibroGen Inc.
- Fresenius SE and Co. KGaA
- Gilead Sciences Inc.
- Ionis Pharmaceuticals Inc.
- KalVista Pharmaceuticals Inc.
- Merck KGaA
- Novartis AG
- Pharming Group NV
- Sino Biological Inc.
- Takeda Pharmaceutical Co. Ltd.
- Thermo Fisher Scientific Inc.
- Vertex Pharmaceuticals Inc.
